Literature DB >> 28179613

Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy - Warfarin vs. Direct Oral Anticoagulants.

Mihoko Kawabata1, Masahiko Goya1, Takeshi Sasaki1, Shingo Maeda1, Yasuhiro Shirai1, Takuro Nishimura1, Takakatsu Yoshitake1, Shinya Shiohira1, Mitsuaki Isobe2, Kenzo Hirao1.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia, associated with increased cardiovascular morbidity and mortality including thromboembolic events. The aims of this study were to assess the prevalence of left atrial appendage (LAA) thrombi in Japanese non-valvular atrial fibrillation (NVAF) patients undergoing preprocedural transesophageal echocardiography (TEE) during anticoagulation therapy, and to compare the efficacy of warfarin and direct oral anticoagulants (DOAC).Methods and 
Results: This retrospective study reviewed records of 559 consecutive NVAF patients (445 men; age, 62±11 years) undergoing preprocedural TEE following at least 3 weeks of anticoagulation therapy. Of these, 275 patients had non-paroxysmal AF (49%). LAA thrombus was observed in 15 patients (2.7%). The prevalence of LAA thrombi was similar between the DOAC group (2.6%) and the warfarin group (2.8%, P=0.86). No patients with CHA2DS2-VASc score=0, or paroxysmal AF without prior stroke or transient ischemic attack, had LAA thrombi. On univariate analysis, non-paroxysmal AF, structural heart disease, antiplatelet therapy, larger left atrium, higher brain natriuretic peptide (BNP), reduced LAA flow, and higher CHA2DS2-VASc score were all associated with LAA thrombi. On multivariate analysis, BNP ≥173 pg/mL remained the only independent predictor of LAA thrombi.
CONCLUSIONS: LAA thrombi were found in 2.7% of Japanese NVAF patients scheduled for procedures despite ongoing oral anticoagulation therapy. Incidence of thrombi was similar for patients on DOAC and on warfarin.

Entities:  

Keywords:  Atrial fibrillation; Direct oral anticoagulant; Left atrial appendage thrombus; Transesophageal echocardiography; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28179613     DOI: 10.1253/circj.CJ-16-1089

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

Review 1.  Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores.

Authors:  Shadi Yaghi; Hooman Kamel
Journal:  Stroke       Date:  2017-09-15       Impact factor: 7.914

Review 2.  Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review.

Authors:  Joana Santos; Natália António; Marília Rocha; Ana Fortuna
Journal:  Br J Clin Pharmacol       Date:  2020-02-05       Impact factor: 4.335

3.  Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation.

Authors:  Xue Zhou; Zuolan Wang; Shuang Dou; Kangyin Chen; Enzhao Liu; Tong Liu; Guangping Li; Jingjin Che
Journal:  Cardiol Res Pract       Date:  2020-06-20       Impact factor: 1.866

4.  How to safely occlude left atrial appendage with a thrombus inside?

Authors:  Şükrü Akyüz; Ilhan Ilker Avcı; Can Yücel Karabay; Duygu Genç; Ali Palice
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

5.  Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Jian Yang; Xuan Zhang; Xi-Ying Wang; Chi Zhang; Song-Zan Chen; Shen-Jiang Hu
Journal:  BMC Cardiovasc Disord       Date:  2019-11-26       Impact factor: 2.298

6.  B-type natriuretic peptide is associated with post-discharge stroke in hospitalized patients with heart failure.

Authors:  Yu Hotsuki; Yu Sato; Akiomi Yoshihisa; Koichiro Watanabe; Yusuke Kimishima; Takatoyo Kiko; Tetsuro Yokokawa; Satoshi Abe; Tomofumi Misaka; Takamasa Sato; Masayoshi Oikawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Yasuchika Takeishi
Journal:  ESC Heart Fail       Date:  2020-06-19

7.  Use of the CHA2DS2VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation.

Authors:  Charlotte Atkinson; Jonathan Hinton; Edmund B Gaisie; Arthur M Yue; Paul R Roberts; Dhrubo J Rakhit; Benoy N Shah
Journal:  Echo Res Pract       Date:  2017-09-01

8.  NT Pro-BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement.

Authors:  Xiao Zhao; Hao Li; Cai Liu; Yuanyuan Ren; Chaofeng Sun
Journal:  Clin Cardiol       Date:  2021-12-24       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.